FIELD: medicine.
SUBSTANCE: invention refers to biochemistry, particularly to monoclonal antibodies binding to c-Met and able to inhibit both ligand-dependent, and ligand-independent c-Met activation. The above antibodies, as well as a composition containing them can be used for producing a therapeutic agent for treating cancer.
EFFECT: invention enables specifically inhibiting both ligand-dependent, and ligand-independent c-Met activation, particularly inhibiting c-Met dimerisation.
34 cl, 111 dwg, 4 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MODELLING MONOCLONAL ANTIBODY ANTAGONISTIC ACTIVITY | 2009 |
|
RU2575600C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 | 2006 |
|
RU2492186C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
